37 Result(s)

Chapter and Conference Paper

Systematic Design of Prognostics and Health Management Solutions for Energy Applications

Nowadays, energy has become a key issue in all sectors of industry. Analytical tools in the prognostics and health management (PHM) area are needed to transform energy and related data into actionable informat...

M. Abuali, E. R. Lapira, W. Zhao, D. Siegel… in Engineering Asset Management 2011 (2014)

Article

Transfer of Natural Micro Structures to Bionic Lightweight Design Proposals

The abstraction of complex biological lightweight structure features into a producible technical component is a fundamental step within the transfer of design principles from nature to technical lightweight so...

M. Maier, D. Siegel, K. -D. Thoben, N. Niebuhr, C. Hamm in Journal of Bionic Engineering (2013)

Article

Hydrology of the Jordan River Basin: Watershed Delineation, Precipitation and Evapotranspiration

The Jordan River Basin is shared between Lebanon, Syria, Israel, Jordan and Palestine; the waters of the River are a critical resource for the future water security of the co-riparians. Because of the politica...

G. F. Comair, D. C. McKinney, D. Siegel in Water Resources Management (2012)

Article

Management of treatment-emergent peripheral neuropathy in multiple myeloma

Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radicu...

P G Richardson, M Delforge, M Beksac, P Wen, J L Jongen, O Sezer, E Terpos… in Leukemia (2012)

Article

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural hist...

S K Kumar, J H Lee, J J Lahuerta, G Morgan, P G Richardson, J Crowley… in Leukemia (2012)

Article

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen

Lenalidomide is an active treatment for multiple myeloma (MM) and is increasingly used as part of the initial treatment of this disease. Recent reports have suggested decreases in the number of CD34+ cells col...

A Nazha, R Cook, D T Vogl, P A Mangan, M Gardler, K Hummel… in Bone Marrow Transplantation (2011)

Article

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Several imaging technologies are used for the diagnosis and management of patients with multiple myeloma (MM). Conventional radiography, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear m...

M Dimopoulos, E Terpos, R L Comenzo, P Tosi, M Beksac, O Sezer, D Siegel… in Leukemia (2009)

Article

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

M A Hussein, F D Vrionis, R Allison, J Berenson, S Berven, E Erdem, S Giralt… in Leukemia (2008)

Article

Blood pressure control in a diabetic population assessed by computer review

A Swislocki, R H Noth, B Volpp, J Meier, D Siegel in Journal of Human Hypertension (2006)

Article

A Graph Theoretic Approach to Strong Monotonicity with respect to Polyhedral Cones

Consider the flow ϕ_t for the system of differential equations \(\dot x\left( t \right) = f\left( x \right)\) , xεΩ, ...

H. Kunze, D. Siegel in Positivity (2002)

Article

Global stability of complex balanced mechanisms

We prove that the ω‐limit set of any solution of a complex balanced chemical reaction mechanism contains either a unique, positive complex balanced equilibrium point, or boundary complex balanced equilibrium p...

D. Siegel, D. MacLean in Journal of Mathematical Chemistry (2000)

Article

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone

The role of more intense conditioning for second transplant was evaluated in myeloma patients achieving at least partial remission (PR) after first transplant with melphalan at 200 mg/m². Forty-three patients rec...

KR Desikan, G Tricot, M Dhodapkar, A Fassas, D Siegel… in Bone Marrow Transplantation (2000)

Article

Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy

Respiratory syncytial virus (RSV) has been reported as a cause of death among autologous peripheral blood stem cell (ASCT) and marrow recipients and recommendations for therapy with aerosolized ribavirin plus ...

T Aslan, A B-T Fassas, R Desikan, D Siegel, NC Munshi… in Bone Marrow Transplantation (1999)

Article

Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-α therapy

Eighty-eight previously autografted (78 transplanted twice and 10 once) myeloma patients who had no cryopreserved stem cells available for possible future use received G-CSF for mobilization of stem cells. One...

S Singhal, J Mehta, K Desikan, D Siegel, J Singh, N Munshi… in Bone Marrow Transplantation (1999)

Article

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

Forty-two patients allografted for multiple myeloma after not having attained at least a partial remission (n = 19) or after having experienced disease progression (n = 23) following one autograft were compared w...

J Mehta, G Tricot, S Jagannath, D Ayers, S Singhal, D Siegel… in Bone Marrow Transplantation (1998)

Article

High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant

Eighteen extensively pre-treated patients (35–73 years, median 46) with relapsed multiple myeloma received salvage chemotherapy with 6 g/m² cyclophosphamide, 800 mg/m² carboplatin, and 1800 mg/m² etoposide (CCV) ...

J Mehta, G Tricot, S Jagannath, KR Desikan, D Siegel… in Bone Marrow Transplantation (1997)